Drugs, diagnostics, real estate, private equity and glass may seem a motley bunch of businesses, but it doesn’t matter how diverse your portfolio is if you can emerge top dog. And it’s leadership that Ajay Piramal is aiming for, reports S. Layak.

An India that's home to 30 of Fortune 100 companies, the world’s largest pool of technically-trained manpower, and Nobel Prize winners in arts, science and literature? That’s management guru C.K. Prahalad’s dream for India@75, and he’s got a plan how to get there. A Business Today exclusive.

Some facts about other management schools in India.

A healthy dose of pharma stocks in your portfolio can be a good defensive strategy in this volatile market.

The market is going through a rough phase as it navigates cross-currents. What should investors do?

The sheer amount of manufacturing activity taking place in small towns of India is mindboggling. Shops are being set up at breakneck speed and there is massive expansion. Where are these clusters located, and can they really deliver on their promise? Here is what Business Today discovered.

India Inc is waking up to nanotechnology, and this promises to change the way you live—whether by arresting the biological ageing process or curing diseases, such as cancer, diabetes and HIV-AIDS, or even bringing out the best from shampoos and airconditioners. A report by Nitya Varadarajan.

Retail and telecom perk up, while IT, ITES and manufacturing slacken, reveals the seventh quarterly BT-TeamLease Employment Outlook Survey.

The most innovative companies don't do different things, they just do things differently. And that seems to make all the difference.

Barriers to innovation remain, but the most innovative companies have realised that \"innovation\" is not just about developing new products and services but, more fundamentally, about discovering new ways to create value. A Business Today-Monitor Group study profiles the most innovative Indian firms.

This Budget was presented in the context of an interesting year from a macro-economic perspective. The year started out on a very positive note with strong economic indicators and a buoyant capital market, but ended with tangible concerns around a slowdown in global growth and its impact on emerging economies like India and China.

Some CEOs liked it, some didn’t, but few could afford to ignore Chidambaram’s 2008-09 budgetary bouquet.

Has the FM done enough to address the potential impact of a US recession on India, exporters reined in by an appreciating rupee and investors caught out by volatile markets?

India’s Pharmaceutical Industry stands fourth in terms of volume and 13th in terms of value. It is valued at over $13 billion (Rs 52,000 crore). While it is export driven, the domestic sector has also done well in recent times.

Indian capital markets increasingly take their cues from global markets. But smart investors have started moving away from stocks that will be affected by the US slowdown. You should, too.

A nondescript town in Kerala is turning into a healthcare hub.

While frontline old economy stocks have been marking new highs, pharma stocks have moved in the opposite direction.  On the face of it, there seems to be plenty wrong.

It’s a move that is likely to help India’s largest IT company get a slice of the humongous budgets of global pharma majors. Last fortnight, TCS announced that it had inked a deal with Swiss pharmaceutical giant Roche to provide a variety of services.

Two of the state's industry-friendly cities, Ahmedabad and Surat, climb up the rankings in the Best Cities for Business survey. That may have something to do with Chief Minister Narendra Modi's avowed goal of achieving economic growth in the state that's even faster than that of China. 

Tarun Sheth answers queries related to your career.